Zymeworks Inc. (NYSE:ZYME) shares traded higher over the last trading session, gaining 0.29% on 02/19/21. The shares fell to a low of $40.84 before closing at $41.14. Intraday shares traded counted 0.24 million, which was 56.29% higher than its 30-day average trading volume of 545.34K. ZYME’s previous close was $41.02 while the outstanding shares total 50.90M. The firm has a beta of 1.10. The stock’s Relative Strength Index (RSI) is 42.88, with weekly volatility at 3.89% and ATR at 2.88. The ZYME stock’s 52-week price range has touched low of $20.33 and a $59.03 high.
Investors have identified the Biotechnology company Zymeworks Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $1.88 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Zymeworks Inc. (ZYME) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 487.32 million total, with 96.89 million as their total liabilities.
Having a look at the company’s valuation, the company is expected to record -4.75 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on ZYME sounds very interesting.
Is the stock of ZYME attractive?
In related news, Chief Financial Officer, Klompas Neil A sold 25,000 shares of the company’s stock in a transaction that recorded on Dec 09. The sale was performed at an average price of 53.25, for a total value of 1,331,133. As the sale deal closes, the Chief Executive Officer, Tehrani Ali now sold 850 shares of the company’s stock, valued at 47,736. Also, Chief Medical Officer, HAUSMAN DIANA sold 6,032 shares of the company’s stock in a deal that was recorded on Dec 04. The shares were price at an average price of 55.12 per share, with a total market value of 332,476. Following this completion of acquisition, the Chief Medical Officer, HAUSMAN DIANA now holds 701 shares of the company’s stock, valued at 38,563. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.70%.
12 out of 14 analysts covering the stock have rated it a Buy, while 2 have maintained a Hold recommendation on Zymeworks Inc.. 0 analysts has assigned a Sell rating on the ZYME stock. The 12-month mean consensus price target for the company’s shares has been set at $57.04.